Anemia Management News

As Akebia Therapeutics announced plans to launch its anemia drug Vafseo to the dialysis community, company officials said they intend to work with the FDA for more testing of the drug for the pre-dialysis market.

LONG BEACH, Calif. — Hydralazine-induced autoimmune conditions may have a varied presentation, including drug-induced lupus or vasculitis, according to a speaker, here.

LONG BEACH, Calif. — Clinicians do not consistently use algorithms for dosing methoxy polyethylene glycol-epoetin beta when treating patients with anemia, presented research shows.

LONG BEACH, Calif. — Researchers reported results from a phase 1b/2a placebo-controlled study of DISC-0974, an anti-hemojuvelin antibody to treat anemia in patients with chronic kidney disease.

Akebia Therapeutics Inc. has received FDA approval for its oral anemia drug Vafseo for treating anemia in adults with end-stage kidney disease on dialysis for at least 3 months.

Healio has compiled a list of its most-read anemia care news in 2023.

PHILADELPHIA — Many kidney transplant patients successfully advance from transplant centers back to their local nephrologists, but providers find there is room for improvement in the transition, according to data presented at ASN Kidney Week.

Healio | Nephrology News & Issues interviewed Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, about the role of anemia management in kidney care. Wish is also chair of the Editorial Advisory Board for Healio | Nephrology News & Issues.

During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to treat anemia in patients with end-stage kidney disease. That has now changed.